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ABSTRACT 
Background: Glycomimetics are a diverse array of saccharide-inspired compounds, designed to mimic the 
bioactive functions of glycosaminoglycans. Therefore, glycomimetics represent a unique source of novel 
therapies to target aberrant signaling and protein interactions in a wide range of diseases. We investigated 
the protective effects of four newly synthesized small molecule glycomimetics against lipid-induced 
endothelial dysfunction, with an emphasis on nitric oxide (NO) and oxidative stress. Methods: Four 
aromatic sugar mimetics were synthesized by the stepwise transformation of 2,5-dihydroxybenzoic acid to 
derivatives (C1-C4) incorporating sulfate groups to mimic the structure  of heparan sulfate. Results: 
Glycomimetic-treated human umbilical vein endothelial cells (HUVECs) were exposed to palmitic acid to 
model lipid-induced oxidative stress. Palmitate-induced impairment of NO production was restored by the 
glycomimetics, through activation of Akt/eNOS signaling. Furthermore, C1-C4 significantly inhibited 
palmitate-induced reactive oxygen species (ROS) production, lipid peroxidation, and activity and 
expression of NADPH oxidase. These effects were attributed to activation of the Nrf2/ARE pathway and 
downstream activation of cellular antioxidant and cytoprotective proteins. In ex vivo vascular reactivity 
studies, the glycomimetics (C1-C4) also demonstrated a significant improvement in endothelium-
dependent relaxation and decreased ROS production and NADPH oxidase activity in isolated mouse 
thoracic aortic rings exposed to palmitate. Conclusions: The small molecule glycomimetics, C1-C4, protect 
against lipid-induced endothelial dysfunction through up-regulation of Akt/eNOS and Nrf2/ARE signaling 
pathways. Thus, carbohydrate-derived therapeutics are a new class of glycomimetic drugs targeting 
endothelial dysfunction, regarded as the first line of defense against vascular complications in 
cardiovascular disease. 
  
Key words: 
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INTRODUCTION 
The vascular endothelium plays a pivotal role in regulating vascular tone, controlling tissue blood flow, 
vessel integrity, permeability, inflammatory responses, vascular remodeling and angiogenesis [1, 2]. 
Pathological conditions can be detrimental to these processes and initiate endothelial dysfunction resulting 
in the development of vascular complications [3, 4], characterized by the reduced bioavailability of nitric 
oxide (NO), which is critical in maintaining the physiological function of vasculature [5]. In addition, an 
imbalance between anti-thrombotic and pro-thrombotic factors predisposes the endothelium to an 
atherogenic milieu, contributing to endothelial dysfunction [6]. Thus, endothelial dysfunction has emerged 
as a critical early target for preventing atherosclerosis and cardiovascular disease [7]. 
 
Endothelial dysfunction is linked to the pathogenesis of common diseases associated with increased risk of 
CVD, including type II diabetes mellitus, obesity and metabolic syndrome [8]. It has been reported that 
chronic elevations in plasma free fatty acids (FFAs) contribute to the development of endothelial damage, 
diminished endothelium-dependent vasodilation, and hypertension [9, 10] by triggering overproduction of 
reactive oxygen species (ROS), leading to uncoupling of eNOS [11]. Palmitic acid, the most prominent 
FFA in the bloodstream, stimulates the production of ROS, at least in part, through activating nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidases and down-regulation of eNOS and associated 
protective pathways, including nuclear factor-erythroid 2-related factor 2 (Nrf2) [12, 13]. Decreasing 
lipotoxicity and its associated oxidative stress, as well as promoting up-regulation of anti-oxidant enzymes 
and cytoprotective proteins, may be key components to prevent and treat cardiovascular diseases. 
The glycosaminoglycan, (GAG) heparan sulfate (HS), is highly sulfated and key to a variety of 
physiological processes, including wound healing, angiogenesis, inflammation and development, [14] often 
acting as a co-receptor for signaling pathways. The multiple biological functions of HS are attributed to 
their variable sulfation patterning, which in turn, allows for diverse but specific ionic interactions between 
the negatively charged sulfates and the carboxylate groups of a variety of proteins, including proteases, 
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growth factors and cytokines [14-16]. HS oligosaccharides can mimic HS functions in biological systems; 
however, their use has been hindered by the complexity of their synthesis [17]. Thus, small molecule 
mimics; glycomimetics, can offer a potential solution to this obstacle [18]. 
 
To the best of our knowledge, there are no published reports regarding the possible protective effects of 
small molecule HS mimetics against lipid-induced endothelial dysfunction. Here, we demonstrate the 
evaluation of a class of small molecule glycomimetics, establishing for the first time their protective effects 
against palmitate-induced endothelial dysfunction, using in vitro and ex vivo models. This study provides 
an understanding of the mechanisms underlying the vascular protective effects of glycomimetics, in terms 
of oxidative stress and endothelial function and their potential as a new class of therapeutic drugs to target 
endothelial dysfunction. 
MATERIALS AND METHODS 
Synthesis of small molecule glycomimetics 
Glycomimetics were synthesized by the stepwise transformation of 2,5-dihydroxybenzoic acid to a range 
of 2,5-substituted benzoic acid derivatives incorporating the key sulfate groups to mimic the interactions of 
HS (Supplementary Fig. I). Namely, commercially available 2,5-dihydroxybenzoic acid was converted to 
the methyl ester using Fischer esterification conditions [19]. In turn, the methyl 2,5-dihydroxybenzoate can 
be mono or di-allylated to afford methyl 5-(allyloxy)-2-hydroxybenzoate or methyl 2,5-
bis(allyloxy)benzoate, respectively [20]. Methyl 5-(allyloxy)-2-hydroxybenzoate can be further alkylated 
with 4-bromobutyl acetate to afford methyl 2-(4-acetoxybutoxy)-5-(allyloxy)benzoate. Either as the methyl 
ester or carboxylic acid the above olefin-containing intermediates were treated with either AD-mix-α or β 
under Sharpless asymmetric dihydroxylation [21] conditions to afford the chiral di or tetra-hydroxylated 
compounds. Finally, treatment with sulfur trioxide-trimethylamine complex gave the desired HS-mimics 
(C1-C4). The chemical methods are described in detail in the Supplementary material online. In total, 4 
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examples of glycomimetics (C1-C4) have been prepared, the structures of which are shown in Figure 1. 
The molecular weights of C1-C4 range from 554-636 Da, total polar surface area (tPSA) are all ≥ 235 A2, 
calculated LogP (octanol/water solubility) ≤ -0.13 and hydrogen bond acceptors ≥ 16, however the number 
of hydrogen bond donating groups are allowable at ≤ 5, therefore, these compounds fall outside the 
Lipinski’s rule of 5 (Ro5) [22], for orally bioavailable drug molecules (Supplementary Table I). This is due 
to the necessary high level of sulfation to mimic HS, but act as a useful starting point for the discovery of 
repurposed glycomimetics. 
Human umbilical vein endothelial cell (HUVEC) culture 
HUVECs (Caltag, Medsystems, Buckingham, UK) from passage 2-7, were cultured in  media (M199; 
Lonza, Belgium) containing 20% fetal bovine serum (FBS), penicillin/streptomycin (2 mmol/L), glutamine 
(2 mmol/L), HEPES (10 mmol/L), endothelial cell growth supplement (30 μg/mL) and heparin (100 µg/mL) 
under 5% CO2 at 37°C.  
Cell viability 
HUVECs were seeded in 96-well microtiter plate and incubated at 37°C for 24 hours. The medium was 
removed, replaced by fresh medium and then exposed to serial dilutions of C1-C4 (1, 10, 100 and 500 
μmol/L) for 24 hours. After incubation, 20 μL of 5 mg/mL MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) in phosphate buffered saline (PBS) was added to the cells and further 
incubated at 37°C for 15 min. After washing, 100 μL of DMSO were added to each well and absorbance 
was measured at 570 nm on a microplate reader (BioTek) with subtraction of the blank value at 630 nm, 
and compared with control untreated cells. 
 
Preparation of palmitate-albumin complexes and cell treatments 
To generate the in vitro model of disease, sodium palmitate was conjugated to bovine serum 
albumin (BSA) as outlined by Chavez and Summers [23], with some modifications. Sodium palmitate was 
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dissolved in ethanol at 60ºC and diluted 1:100 in M199 media supplemented with 2% fatty acid-free bovine 
serum albumin (BSA) and incubated for 1 hour at 37ºC. HUVECS were treated with 1 µmol/L of the 
synthesized glycomimetics (C1-C4) in the presence of palmitate (100 µmol/L) for 3 hours or pre-treated 
with glycomimetics for 12 hours followed by 3 hours palmitate (100 μmol/L). In some experiments, 
HUVECs were incubated with 1, 10 or 100 µmol/L of the test compounds (C1-C4). Control cells were 
incubated in serum free M199 containing 2% (wt/vol) fatty acid-free BSA. 
NO release assay 
NO release was determined using, diaminofluorescein-2 (DAF-2) [24]. Briefly, cells were washed with 
PBS and incubated with L-arginine (100 μmol/L /PBS) for 5 min at 37ºC before incubating with DAF-2 
(0.1 μmol/L) for 2 min, followed by the calcium ionophore calimycin (A23187, 1 μmol/L) for 30 minutes. 
L-NAME (100 μmol/L), a nitric oxide inhibitor (NOS), was also added 20 min before the addition of L-
arginine in some experiments to demonstrate the involvement of NOS. DAF-2 fluorescence (arbitrary units, 
AU) was quantified using a microplate reader (BioTek) with excitation and emission wavelengths of 485 
and 540, respectively. The autofluorescence was subtracted from each value. 
Quantification of ROS production 
Cells were incubated with 10 µmol/L of the fluorescent probe 2’-7’-dichlorodihydrofluorescein diacetate 
(CM-H2DCFDA, Sigma) for 30 min at 37ºC and the level of fluorescence was determined (excitation 490 
nm; emission 540 nm) using a microplate reader (BioTek). 
 
NADPH oxidase activity 
The level of NADPH-enhanced superoxide anions (O2•−) in HUVEC homogenates or intact mouse aortic 
rings was determined by lucigenin-enhanced chemiluminescence, as demonstrated previously [25]. 
Following the various treatment conditions, cells or aortic rings were homogenized in a buffer (20 mmol/L 
KH2PO4 and 1 mmol/L EDTA supplemented with aprotinin, leuprotinin, pepstatin and PMSF) and the total 
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protein quantified using the Bicinchoninic acid (BCA) assay (Pierce Biotechnology). To 50 μg of total 
protein, NADPH (100 μmol/L) was added in a total volume of 500 μl, with lucigenin (5 μmol/L) injected 
automatically. Activity was determined by measuring luminescence over 200 s in a scintillation counter 
(Lumat LB 9507, Berthold, Germany). Basal values of NADPH oxidase activity were subtracted from the 
experimental values and expressed as RLU/min/μg protein for cells or RLU/min/mg tissue for aortic rings. 
 
Lipid peroxidation assay 
The OxiSelect TBARS assay kit (Cell Biolabs, San Diego, USA) was used to determine the level of lipid 
peroxidation by measuring malondialdehyde (MDA). After treatment, HUVECs were washed with PBS 
and homogenized in RIPA buffer. SDS lysis solution was added to the samples and MDA standards 
followed by incubation with thiobarbituric acid for 45 minutes at 95°C. Samples were cooled to room 
temperature and centrifuged at 1000 g for 15 min. The supernatant was removed and the absorbance was 
measured at 532 nm using a microplate reader (BioTek). Lipid peroxidation was expressed as nmol 
MDA/mg protein. 
 
Superoxide dismutase (SOD) and catalase (CAT) activity assays 
The activity of the enzymes, SOD and CAT, was determined in cell homogenates using  assay kits (Cayman; 
Cat No 706002 and 707002 respectively), according to the manufacturer’s instructions. A unit of SOD was 
defined as the amount of enzyme required to demonstrate 50% dismutation of superoxide radicals. 
Similarly, a unit of CAT was defined as the amount required to the form 1.0 nmol of formaldehyde per min 
at 25ºC. 
 
Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis 
Trizol (Invitrogen) was used to isolate total RNA from HUVECs and was quantified at 260 nm using a 
Nanodrop. RNA samples with A260/A280 ratios < 1.7 were discarded. cDNAs were synthesized from total 
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RNA (2 µg), using an oligo deoxythymidine primer and SuperScript II reverse transcriptase (Sigma) and 
were amplified using the SYBR Green master mix (Bioline, UK) in a total volume of 20 µl (Surecycler 
8800 thermocycler; Agilent Technologies) with the primer sets outlined in Supplementary Table II. Real-
time PCR was performed using the following conditions; 10 min at 95°C, followed by 40 cycles of 30 sec 
at 95ºC, 60 sec at annealing temperature of respective primer set, and extension for 30 sec at 72ºC. PCR 
products were assessed for quality using standard melting curve analysis and an agarose gel electrophoresis. 
The cycle threshold (CT) values were analyzed using the 2-ΔΔCt method and data normalized to GAPDH. 
 
Western blot analysis 
HUVECs were lysed in RIPA buffer, containing proteinase inhibitors and total protein quantified using 
BCA protein assay kit (Pierce Biotechnology). Proteins (30 μg/well) were denatured and separated by 
sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis and transferred to polyvinylidene 
difluoride (PVDF) membranes. Blots were blocked for 1 hour in 5% non-fat milk/Tris-Buffered Saline 
Tween-20 (TBS-T), probed with primary rabbit anti-phospho-protein kinase B (Akt), rabbit anti-Akt (Santa 
Cruz Biotechnology), rabbit polyclonal anti- phospho-eNOS (Cell Signaling), rabbit anti-eNOS, rabbit anti-
HO-1 (Stressgen), rabbit anti-Nrf2, rabbit anti-NQO-1 (Santa Cruz Biotechnology) or mouse anti-β-actin 
(Sigma), overnight at 4ºC followed by washing and incubation with the corresponding horse radish 
peroxidase-labelled secondary antibody for 1 hour at room temperature. After washing with TBS-T, 
membranes were incubated with ECL reagent and visualized  (Amersham Pharmacia Biotech). 
Densitometry analysis using ImageJ (version 1.32j, NIH, http://rsb.info.nih/ij/) was used to quantify protein 
signal. 
 
Ex vivo vascular reactivity 
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Thoracic aortas from the experimental male BALB/c mice (Janvier, St Berthevin Cedex, France) were 
harvested, cleared of periadventitial tissue and cut transversely into 2.0-mm rings. All the procedures 
conform to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health (NIH) 
publication no. 85-23, revised 2011) and approved by the Institutional Committee for the ethical care of 
animals (University of Granada, Spain). Mouse thoracic aortic (MTA) rings were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% FBS, and antibiotics  (100 U/mL penicillin, 
and 100 μg/mL streptomycin). MTA rings were then incubated in serum-free DMEM containing 2% fatty 
acid-free BSA (control) or palmitate-conjugated BSA (100 μmol/L) in the presence of glycomimetics (1 or 
10 μmol/L) for a 24 hour duration. Care was taken with the vascular rings to avoid damage of the endothelial 
layer and  transferred to a chamber filled with fresh Kreb’s solution and mounted in a myograph (model 
610M, Danish Myo Technology, Aarhus, Denmark) for isometric tension measurement, as described 
previously [26]. Cumulative dose–response relaxation curves to acetylcholine (ACh; 1 nmol/L – 10 
µmol/L) were performed in intact rings pre-contracted by U46619 (10 nmol/L) in control or L-NAME (100 
μmol/L)-treated aortic rings. The mouse aorta were incubated with mitochondrial antioxidant mitoQ (0.1 
µmol/L) or the NADPH oxidase inhibitor apocynin (10 µmol/L) for 60 min before the addition of U46619 
to establish the source of  ROS following palmitate treatment and relaxant responses to ACh were 
subsequently measured and expressed as a percentage of pre-contraction. 
In situ detection of vascular ROS content 
MTA rings were incubated in serum-free DMEM containing 2% fatty acid-free BSA (control) or palmitate 
conjugated BSA (100 μmol/L) in the presence of glycomimetics (1 or 10 μmol/L) for 24 hours. Unfixed 
MTA rings were cryopreserved in 0.1 mol/L PBS plus 30% sucrose for 1 hour, included in OCT compound 
medium (Tissue-Tek; Sakura Finetechnical), and kept frozen (−80ºC). By using a cryostat (Microm 
InternationalModelHM500 OM), 10 μm cross sections were obtained and incubated for 30 min in Hepes-
buffered solution containing 10 µmol/L dihydroethidium (DHE), which incalates with DNA in the presence  
of ROS and is detected by fluorescence. Cells were counterstained with the nuclear stain DAPI at 0.3 
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µmol/L. In the following 24 hours, sections were examined using a fluorescence microscope (Leica 
DMIRB,). Sections were photographed and fluorescence was quantified using ImageJ. All parameters 
(pinhole, contrast, gain and offset) were held constant for all sections from the same experiment. ROS 
production was estimated from the ratio of ethidium/DAPI fluorescence [27]. 
 
Statistical analysis 
Data were analysed using GraphPad Prism 5 (GraphPad Software, San Diego, USA) and comparisons were 
made using one-way analysis of variance (ANOVA) test and Tukey’s post-hoc analysis. Two-way ANOVA 
tested for group interactions and results were expressed as mean ± standard error of the mean and P=≤ 0.05 
was considered significant. 
RESULTS 
Glycomimetics do not affect cell viability 
We tested the effects of glycomimetics C1-C4 (Fig.1) on HUVEC viability using concentrations ranging 
from 1 to 500 μmol/L. After incubation for 24 hours, no detrimental effects on HUVEC viability was 
detected with any glycomimetic compound at any concentration (Supplementary Fig. II). 
 
Glycomimetics rescue palmitate-induced impairment of NO production 
First, to study the concentration-dependent effect of the synthesized glycomimetics on NO production, 
HUVECs were incubated with 1, 10 or 100 µmol/L of the test compounds (C1-C4) for 12 hours, followed 
by 3 hours palmitate (100 μmol/L). C1 significantly increased A23187-stimulated NO production from 
HUVECs at the 1 μmol/L (P<0.05), 10 μmol/L (P<0.001) and 100 μmol/L (P<0.01) concentrations 
(Supplementary Fig. IIIA). Pre-treatment with different doses of C2 significantly (P<0.001) protected 
HUVECS against palmitate-induced reduction in NO (Supplementary Fig. IIIB). The lower dose (1 μmol/L) 
of C3 produced a significant (P<0.05) increase in A23187-stimulated NO production from HUVECs and 
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the higher doses (10 and 100 μmol/L) produced a more potent effect (P<0.001, Supplementary Fig. IIIC). 
Similar to C1, C4 significantly increased NO production from HUVECs at the 1 μmol/L (P<0.05), 10 
μmol/L (P<0.001) and 100 μmol/L (P<0.01) concentrations (Supplementary Fig. IIID). In HUVECs treated 
with 3 different doses of C1, C2, C3 or C4, the eNOS inhibitor L-NAME significantly (P<0.001) abolished 
A23187-stimulated NO production from HUVECS when compared with the corresponding glycomimetic 
dose.  However, in light of the consistent response with all four compounds, we selected to use the low 
dose of 1 μmol/L for all future glycomimetic treatments. 
 
Next, to determine the restorative effect of the glycomimetics on palmitate-induced reduction in NO 
production, HUVECs were incubated either with 1 µmol/L of the synthesized glycomimetics (C1-C4) in 
the presence of palmitate (100 µmol/L) for 3 hours, or pre-treated with glycomimetics for 12 hours followed 
by 3 hours palmitate (100 μmol/L) respectively. HUVECs incubated with palmitate, exhibited a significant 
(P<0.001) decrease in A23187-stimulated NO production. In HUVECs pre-treated with palmitate, followed 
by  incubation with C1, C2, C3 or C4 for 3 hours, the dramatic decrease in NO production was significantly 
(P<0.001) attenuated compared to palmitate controls (Fig. 2A). Pre-incubation with 1 µmol/L C1-C4, 
significantly protected HUVECs against the significant decline in A23187-stimulated NO production in the 
presence of palmitate (Fig. 2B).  
 
Glycomimetics modulate mRNA and phosphorylation levels of eNOS and Akt under palmitate-
induced oxidative stress 
To determine whether the enhanced NO release observed after treatment with glycomimetics under 
palmitate-induced stress conditions was due to activation of the Akt/eNOS pathway, both the level of 
mRNA abundance and protein phosphorylation of Akt and eNOS were investigated. HUVECs were pre-
incubated with 1 µmol/L of the glycomimetics (C1-C4), followed by palmitate for 3 hours. Palmitate 
treatment alone produced a marked decline in both Akt mRNA (P<0.01, Fig. 3A) and protein 
phosphorylation (pAkt; P<0.05, Fig. 3B). Pretreatment of HUVECs with C1, C2, C3 or C4 significantly 
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(P<0.05) increased Akt mRNA abundance, and Akt protein phosphorylation, with pAkt restored to 
untreated control levels. A more marked effect in terms of Akt phosphorylation (P<0.01) was observed with 
C4. 
 
Similarly, palmitate significantly reduced eNOS mRNA abundance (P<0.01, Fig. 3C) and protein 
phosphorylation (peNOS; P<0.05, Fig. 3D) in HUVECs treated for 3 hours. eNOS mRNA abundance 
exhibited a marked increase in HUVECS pretreated with C1 (P<0.05), C2 (P<0.01), C3 (P<0.05) or C4 
(P<0.05). There was a significant increase in eNOS protein phosphorylation in HUVECs pretreated with 
C1 (P<0.05), C2 (P<0.05), C3 (P<0.05) or C4 (P<0.001) followed by palmitate treatment, compared to 
palmitate-treated controls, with the greatest effect observed with C4. Again, peNOS was restored to 
untreated control levels when pre-treated with all four glycomimetics. 
 
Glycomimetics attenuate palmitate-induced ROS production and oxidative stress 
Next, we investigated the effect of the glycomimetics on palmitate-induced oxidative stress by assessing 
ROS production, lipid peroxidation and activity of the antioxidant enzymes, SOD and CAT. HUVECs 
treated with palmitate for 3 hours exhibited a significant (P<0.001) increase in ROS production as expected. 
This ROS induction was significantly reduced (P<0.001) after co-treatment with 1 µmol/L of C1, C2, C3 
or C4 to untreated control levels (Fig. 4A). The same protective effect was apparent when pre-treated with 
C1-C4 for 12 hours (P<0.001; Fig. 4B. The concentration-dependent effect of the glycomimetic compounds 
C1-C4 on palmitate-induced ROS production was also studied in the pre-treatment model. All compounds 
at the different doses (1, 10 or 100 µmol/L) significantly abolished the palmitate-induced ROS production 
to the same extent and to untreated control levels (Supplementary Fig. IV). 
 
Supporting the ROS data, lipid peroxidation (assayed as MDA) showed a significant (P<0.001) increase in 
HUVECs treated with palmitate for 3 hours which was significantly reduced (P<0.05) after pretreatment 
with 1 µmol/L C1-C4, (Fig. 4C). 
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The activity of the anti-oxidant enzyme SOD was, as expected significantly (P<0.01) decreased in HUVECs 
treated with palmitate for 3 hours, an effect which was prevented when pre-treated with glycomimetic C1 
(P<0.05), C2 (P<0.001), C3 (P<0.001) or C4 (P<0.01; Fig. 4D). CAT activity exhibited a similar pattern 
where it was significantly (P<0.001) lower in palmitate treated cells and restored to untreated control levels 
in HUVECs pretreated with C1 (P<0.01), C2 (P<0.01), C3 (P<0.001) or C4 (P<0.05) glycomimetics, with 
C3 showing the most marked effect (Fig. 4E). 
 
Glycomimetics reduce palmitate-stimulated NADPH oxidase activity 
To further validate the protective effect of the glycomimetic compounds C1-C4 against palmitate-induced 
oxidative stress, NADPH oxidase activity and mRNA expression of its subunits were assayed. Palmitate 
induced a significant (P<0.001) increase in NADPH oxidase activity when compared with untreated control 
HUVECs. Pretreatment with 1 µmol/L C1-C4 significantly (P<0.001) decreased NADPH oxidase activity 
in palmitate-treated HUVECs (Fig. 5A). Furthermore, HUVECs treated with palmitate for 3 hours exhibited 
a significant increase in mRNA abundance of the NADPH oxidase subunits p22phox (P<0.001; Fig. 5B), 
NOX1 (P<0.001; Fig. 5C), NOX4 (P<0.01; Fig. 5D), and p47phox (P<0.001; Fig. 5E). However, in the 
presence of all 4 glycomimetics, a significant protective effect was detected with a down-regulation of 
mRNA abundance of NOX1, NOX4, p47phox and p22phox (Figure 5, P<0.05) compared to palmitate alone. 
 
Glycomimetics protect against palmitate-induced oxidative stress via the Nrf2/ARE pathway 
To establish the downstream protective anti-oxidant effects of the glycomimetic compounds C1-C4, against 
palmitate-induced oxidative stress, mRNA and protein expression of Nrf2, NQO-1 and HO-1 were 
interrogated using qRT-PCR and western blotting, respectively (Fig. 6).  
 
Under palmitate-induced oxidative stress conditions, a significant reduction in the mRNA abundance and 
protein levels of Nrf2, NQO-1 and HO-1 was observed, when compared to homeostatic controls (Fig. 6). 
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Palmitate-induced HUVECs exhibited a significant up-regulation and restoration of Nrf2, NQO-1 and HO-
1 mRNA abundance when pretreated with C1 (P<0.001), C2 (P<0.01), C3 (P<0.01) or C4 (P<0.001) (Fig. 
6). In support of the mRNA data, a correlation was found with, Nrf2, NQO-1 and HO-1 protein expression 
where we demonstrate a significant increase in HUVECs pretreated with C1 (P<0.05), C2 (P<0.01), C3 
(P<0.001) or C4 (P<0.05), with C2 and C3 exhibiting the most potent effects (Fig. 6). 
 
Glycomimetics restore endothelium-dependent vasodilatation ex vivo after palmitate treatment 
In order to establish whether these effects could be validated in a more physiological model, an ex vivo 
contractility study was conducted to evaluate the effect of C1-C4 treatment on the endothelium-dependent 
vasodilatation (Fig. 7). Mouse aortic rings were incubated with 100 µmol/L palmitate and 1 or 10 µmol/L 
of C1-C4 for 24 hours and concentration-relaxation response curves to ACh were performed in intact rings 
pre-contracted by the prostaglandin analog, U46619. 
 
Aortas treated with palmitate showed a significant (P<0.001) decrease in endothelium-dependent 
vasodilator responses to ACh, compared with the control aortas. C1 and C2, at both doses (1 and 10 
µmol/L), significantly (P<0.001) improved the palmitate-reduced endothelium-dependent vasodilatation 
(Fig. 7A and B, respectively). Both doses of C3 produced a significant (P<0.01) increase in endothelium-
dependent vasodilatation when compared with the palmitate-induced aortas (Fig. 7C). However, the 
improved endothelium-dependent vasodilatation produced by C3 treatment was significantly (P<0.05) 
lower than the control aortas. The lower concentration of C4 (1 µmol/L) showed a marked (P<0.01) 
alleviation in endothelium-dependent vasodilatation, but was still significantly (P<0.01) lower than the 
control aortas (Fig. 7D). The higher dose of C4 (10 µmol/L) significantly (P<0.001) improved endothelium-
dependent vasodilatation when compared with the palmitate-induced aortas and was similar to untreated 
controls. 
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To validate the endothelial-dependent relaxation responses to ACh, the eNOS inhibitor L-NAME was 
added, which abolished the relaxant response induced by ACh in all experimental groups as shown in 
Supplementary Figure V. To examine whether ROS are involved in endothelial dysfunction induced by 
palmitate in mouse aorta, the endothelium-dependent relaxant response to ACh in the presence of the 
mitochondrial antioxidant mitoQ (Fig. 7E) or the NADPH oxidase inhibitor apocynin were analyzed (Fig. 
7F). Both mitoQ and apocynin significantly improved the impaired aortic relaxation in response to ACh 
induced by palmitate, suggesting involvement of ROS-induced pathways. 
 
Glycomimetics attenuate palmitate-induced vascular ROS levels by reducing NADPH oxidase 
activity ex vivo 
To characterize and localize ROS levels within the vascular wall, aortic rings were incubated with 100 
µmol/L palmitate and 1 or 10 µmol/L of C1-C4 for 24 hours and the level of red fluorescence was 
determined in sections of aorta incubated with DHE (Fig. 8A). Rings treated with palmitate showed 
significantly (P<0.001) increased staining in adventitial, medial and endothelial cells compared with the 
control group. Sections from palmitate-treated rings exhibited a marked decrease in red fluorescence 
(P<0.01) when co-incubated with any glycomimetic at either dose, suggesting attenuation of ROS 
production. 
 
NADPH oxidase activity measured by lucigenin-enhanced chemiluminescence (Fig. 8B) was significantly 
(P<0.001) increased by palmitate. Co-incubation of aortic rings with either dose of C1or C2 significantly 
(P<0.001) reduced NADPH oxidase activity when compared to palmitate alone. C3 significantly decreased 
NADPH oxidase activity at both the 1 (P<0.01) and 10 µmol/L (P<0.001) doses. C4 exhibited a similar 
pattern as it significantly (P<0.01) reduced NADPH oxidase activity at both applied concentrations. 
 
DISCUSSION 
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Glycosaminoglycans represent the most abundant class of molecules in nature. They are involved in disease 
indications; however, they lack the properties necessary for efficacious drugs. Therefore, design and 
synthesis of small molecule glycomimetics, exhibiting drug-like properties could represent a new class of 
therapeutic drugs to target molecular mechanisms of disease [18, 28]. Here, we report the discovery and 
evaluation of the effects of glycomimetics in a FFA-induced model of endothelial dysfunction. We 
demonstrate that glycomimetics exert protective effects against palmitate-induced endothelial dysfunction. 
Our data point to the involvement of Akt/eNOS and Nrf2/ARE signaling pathways in mediating these 
protective effects on the endothelium. 
HUVECs were used in both a pre-treatment and co-incubation regime to reflect a potential preventative 
mechanism and possible treatment of disease in progress respectively. Palmitate-treated HUVECs showed 
diminished A23187-stimulated NO production mediated via reduced Akt-dependent phosphorylation of 
eNOS at Ser1177. This observation confirms previous work demonstrating palmitate induced eNOS 
uncoupling, decreased eNOS phosphorylation and ultimately NO production [11, 26]. We show that small 
molecule glycomimetics markedly prevented the palmitate-induced decline in NO production through up-
regulation of the mRNA abundance and protein phosphorylation of both Akt and eNOS. 
The FFA-induced decline in NO production could be explained by the overproduction of ROS. Palmitic 
acid stimulates the production of superoxide radicals through activating NADPH oxidases and down-
regulation of eNOS [12, 13]. Superoxide reacts with NO, forming the potent and versatile oxidant 
peroxynitrite (ONOO•−) which may oxidize the eNOS cofactor tetrahydrobiopterin or destabilize the eNOS 
dimer, causing uncoupling of eNOS [29]. Uncoupled eNOS produces superoxide rather than NO, thus 
further augmenting oxidative stress and decreasing NO bioavailability [29]. In addition, ROS activates 
membrane oxidases leading to increased dimethylarginine, an arginine decoy for the active sites on eNOS 
and L-arginine transporters [30]. Here, palmitate induced a marked increase in ROS production through 
activating NADPH oxidase, as previously reported [26, 31, 32]. In addition, we demonstrated increased 
expression of the NADPH oxidase subunits, NOX1, NOX4, p22phox and p47phox, in palmitate-induced 
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HUVECS. The formation of ROS is further aggravated by reduced antioxidant defenses, leading to 
oxidative damage and endothelial cell dysfunction [33]. The intracellular antioxidant system includes SOD 
and CAT that metabolize toxic oxidative stress intermediates; SOD catalyzes the conversion of superoxide 
to H2O2 and O2 and CAT converts H2O2 to water [34] and given that we demonstrate a significant restoration 
of SOD and CAT activity in the presence of C1-C4, we propose that  reducing ROS production by these 
glycomimetic compounds act  in the management of FFA-induced endothelial dysfunction and vascular 
complications. 
Small molecule glycomimetics were able to reduce ROS production through decreasing NADPH oxidase 
activity and down-regulating the expression of its subunits. Moreover, the tested glycomimetics decreased 
lipid peroxidation, an important intermediary process in oxidative stress, and ameliorated intracellular 
redox status, as shown by the enhanced activity of SOD and CAT. The potentiation of antioxidant defenses 
and normalization of ROS would appear to contribute to the restoration of endothelial function. 
To understand the molecular basis for the protective effects of the glycomimetics, we hypothesized a 
specific mechanism that could be associated to their potential, to elicit cell adaptive responses involving 
the transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2). Nrf2 is a ubiquitous transcription 
factor, which plays an important role in cellular resistance to oxidative stress. The Nrf2 protein is 
sequestered in the cytosol, by the actin-binding protein, Kelch-like ECH-associated protein 1 (Keap1). 
Under physiological conditions, Keap1 serves as an adapter for cullin 3 (Cul3)/ring-box 1 (Rbx1)-mediated 
ubiquitination and degradation of Nrf2, which decreases Nrf2 activity [35]. The generation of ROS causes 
KEAP1 to undergo a conformational change, thus, dissociating from Nrf2, which in turn, translocates to 
the nucleus. Within the nucleus, it regulates antioxidant response element (ARE)-mediated expression of 
anti-oxidant enzyme and cytoprotective proteins, including the transcription of downstream target genes, 
such as NAD(P)H:quinone oxido-reductase 1 (NQO1), heme oxygenase-1 (HO-1), glutathione peroxidase 
(GPx) and the superoxide dismutase (SOD) family [36, 37] and CAT [31, 38]. 
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We therefore tested the hypothesis that Nrf2 activation plays a crucial role in protecting the endothelium 
from oxidative injury when endothelial cells were treated with palmitate. Our results demonstrate a 
significant decline in Nrf2 and its downstream cytoprotective proteins. These findings could be explained 
in terms of palmitate-induced overproduction of ROS. It has been reported by Mann et al. [39] that the basal 
activity of NADPH oxidase produces ROS which activate Nrf2/ARE-mediated antioxidant genes in order 
to maintain redox homeostasis. However, in this acute model, using palmitate, we suggest that excessive 
ROS production enhances the feedback mechanism and leads to Nrf2 down-regulation. Our hypothesis is 
based on results of studies demonstrating down-regulation of Nrf2 pathway under oxidative stress 
conditions. In this context, oscillating high glucose [40] and disturbed shear stress on the vascular wall 
resulting from oscillatory blood flow [41], diminishes the Nrf2-mediated activation of ARE-linked genes. 
A high-fat diet also evoked a significant increase in the mRNA abundance of HO-1 in the aortas of Nrf2+/+ 
mice but not Nrf2-/- mice, suggesting that adaptive activation of the Nrf2/ARE pathway confers endothelial 
protection [42]. More recently, Fratantonio et al. [43] reported a significantly down-regulated Nrf2, NQO-
1 and HO-1 expression in HUVECS exposed to palmitic acid for 3 hours, lending support for the findings 
of this study. 
For the first time, we demonstrate that small molecule glycomimetics are able to induce Nrf2 under FFA 
conditions, thus protecting against oxidative stress. As a consequence of Nrf2 activation, NQO-1 and HO-
1 gene and protein expression was up-regulated following glycomimetic pretreatment. Multiple studies 
support the notion that induced expression of Nrf2/ARE-regulated cytoprotective proteins may contribute 
to the atheroprotective phenotype in endothelial cells [44,45]. A negative feedback regulatory loop between 
NADPH oxidase and Nrf2 has been suggested. Under homeostatic conditions, NOX4 generates superoxide 
and H2O2 which activate Nrf2 by inactivating Keap1 [46]. The activated Nrf2 then inhibits the transcription 
of NOX4 to lower ROS production [47,48]. HO-1 reduces oxidative stress-induced cell damage by restoring 
the balance of antioxidants and pro-oxidants in the vasculature. HO-1 is also known to degrade the pro-
oxidant haem to biliverdin, which is subsequently converted to the radical scavenger bilirubin [49]. By 
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interrupting the assembly and activation of the enzyme, bilirubin may directly inhibit NADPH oxidase in 
endothelial cells, both in vitro and in vivo [50,51]. Hence, Nrf2/HO-1 pathway represents a key adaptive 
mechanism for moderating the severity of oxidative stress provoked cell damage. 
Having demonstrated the protective effects of small molecule glycomimetics on FFA-induced endothelial 
dysfunction in vitro, we have evaluated their effects on endothelium-dependent vasodilatation and ROS 
production ex vivo in the presence of palmitate. Mouse aortic rings incubated with palmitate for 24 hours 
exhibited impaired ACh-induced relaxation. The diminished vasodilatation was associated with increased 
NADPH oxidase activity and ROS production, confirmed by DHE staining, in palmitate-induced mouse 
aortic rings, in agreement with Toral et al. [26]. They also reported diminished endothelium-dependent 
vasodilatation in aortas from high fat diet-fed mice. When the NADPH oxidase inhibitor apocynin and the 
mitochondrial antioxidant mitoQ were applied, both partially counteracted the palmitate-induced 
impairment of endothelium-dependent vasodilatation, strengthening the findings of Toral et al. [26], thus 
confirming activation of oxidative stress pathways. Of note, all tested small molecule glycomimeticis were 
able to improve endothelium-dependent relaxation, diminish ROS production and decrease activity of 
NADPH oxidase in mouse aortic rings. Moreover, incubation of the aortic rings with a high concentration 
of the eNOS inhibitor L-NAME almost abolished the ACh-induced vasodilatation, indicating that it is 
completely dependent on eNOS-derived NO. These findings suggest that small molecule glycomimetics 
exert their effects on vascular relaxation, mainly through inhibition of ROS production and an increase in 
NO bioavailability. 
 
In conclusion, we provide the first evidence that small molecule glycomimetics exert protective effects 
against FFA-induced endothelial dysfunction. Our mechanistic evidence suggests the involvement of 
Akt/eNOS and Nrf2/ARE signaling pathways in mediating the effects of glycomimetics, summarized 
schematically in Figure 9. These chemical probes increased NO bioavailability through their ability to 
positively regulate Akt and eNOS gene expression as well as protein phosphorylation. In addition, the 
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coordinate induction of cytoprotective proteins through activation of the Nrf2/ARE pathway potentially 
protected the endothelium against FFA-induced oxidative stress. Therefore, small molecule glycomimetics 
represent a field of great interest for application in the prevention and therapy of FFA-induced endothelial 
dysfunction as well as for other diseases related to oxidative stress and warrant further investigation. 
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Figure legends: 
Figure 1. The four glycomimetics C1-C4 synthesized and used in this study. 
Figure 2. Glycomimetics rescue palmitate-induced impairment of NO production. HUVECS incubated 
with 1 µmol/L of the glycomimetics C1-C4 in the presence of palmitate for 3 hours (A) or pretreated with 
C1-C4 for 12 hours followed by 3 hours palmitate (B). Treatment with either 1 µmol/L C1-C4 for 3 hours 
along with palmitate or for 12 hours followed by the addition of palmitate for 3 hours protects against 
palmitate-induced reduction in NO production. Results are mean ± SEM; N = 8-12. ***P<0.01 versus 
control, and #P<0.05, ##P<0.01 and ###P<0.001 versus PAL. PAL, palmitate; AUC, area under curve; 
DAF-2, diaminofluorescein-2. 
 
Figure 3. Glycomimetics modulate mRNA abundance and protein phosphorylation of eNOS and Akt 
under palmitate-induced oxidative stress. HUVECs were pretreated with C1-C4 for 12 hours followed 
by 3 hours of palmitate. Treatment with palmitate decreases both Akt mRNA (A) and protein 
phosphorylation (B), and reduces mRNA (C) and phosphorylation of eNOS (D). All tested glycomimetics 
at 1 µmol/L concentration up-regulate Akt and eNOS mRNA abundance and phosphorylation in HUVECs 
treated with palmitate. Results are mean ± SEM; N = 6. *P<0.05 and **P<0.01 versus control, and #P<0.05, 
##P<0.01 and ###P<0.001 versus PAL. PAL, palmitate; Akt, protein kinase B; eNOS, endothelial nitric 
oxide synthase. 
 
Figure 4. Glycomimetics reduce palmitate-induced ROS production and oxidative stress. 
Glycomimetics exhibit protective effect against palmitate-induced ROS production in HUVECS either 
incubated with 1 µmol/L C1-C4 in the presence of palmitate for 3 hours (A) or pretreated with C1-C4 for 
12 hours followed by 3 hours palmitate (B). HUVECs treated with palmitate for 3 hours show significant 
increase in MDA, a marker of lipid peroxidation (C), and concomitant decrease in the activity of SOD (D) 
and CAT (E). Pretreatment with 1 µmol/L C1-C4 prevent palmitate-induced lipid peroxidation and 
diminished activity of antioxidant enzymes in HUVECs. Results are mean ± SEM; N = 6-10. **P<0.01 and 
***P<0.001 versus control, and #P<0.05, ##P<0.01 and ###P<0.001 versus PAL.  PAL, palmitate; ROS, 
reactive oxygen species; MDA, malondialdehyde, SOD, superoxide dismutase; CAT, catalase. 
 
 
Figure 5. Glycomimetics modulate NADPH oxidase activity in HUVECs in response to palmitate. 
HUVECS pretreated with C1-C4 for 12 hours followed by 3 hours palmitate. (A) NADPH oxidase activity 
measured by lucigenin-enhanced chemiluminescence. (B-E) Expression of NADPH oxidase subunits 
NOX1, NOX4, p22phox and p47phox at the level of mRNA by RT-PCR. Palmitate increases both NADPH 
oxidase activity and expression of the enzyme subunits. C1-C4 reduce palmitate-induced NADPH oxidase 
activation and expression in HUVECs treated 12 hours with the addition of palmitate for 3 hours. Results 
are mean ± SEM; N = 6-8. **P<0.01 and ***P<0.001 versus control, and #P<0.05, ##P<0.01 and 
###P<0.001 versus PAL. PAL, palmitate; NADPH oxidase, nicotinamide adenine dinucleotide phosphate 
oxidase. 
 
 
Figure 6. Glycomimetics protect against palmitate-induced oxidative stress via the Nrf2/ARE 
pathway. The effect of C1-C4 and palmitate treatment on HUVECs with regard to Nrf2 (A & B), NQO-1 
(C & D) and HO-1 (E & F) levels was determined using qRT-PCR and western blotting. Treatment with 
palmitate produces a significant decrease in both mRNA and protein levels of Nrf2, NQO-1 and HO-1. 
Pretreatment with 1 µmol/L C1-C4 increases levels of Nrf2, NQO-1 and HO-1 in HUVECs treated with 
palmitate. Results are mean ± SEM; N = 6. *P<0.05, **P<0.01 and ***P<0.001 versus control, and 
#P<0.05, ##P<0.01 and ###P<0.001 versus PAL. PAL, palmitate; Nrf2, nuclear factor-erythroid 2-related 
factor 2; NQO-1, NAD(P)H:quinone oxido-reductase 1; HO-1, heme oxygenase-1. 
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Figure 7. Glycomimetics restore endothelium-dependent vasodilatation ex vivo. Mice aortic rings were 
incubated with 100 µmol/L palmitate and 1 or 10 µmol/L of (A) C1, (B) C2, (C) C3 or (D) C4 for 24 hours. 
Concentration-relaxation response curves to ACh were performed in intact rings pre-contracted by U46619. 
Treatment of aortic rings with palmitate for 24 hours diminished endothelium-dependent vasodilator 
responses to ACh, an effect that was significantly reversed by either dose of the glycomimetics C1-C4. (E 
& F) ROS are involved in endothelial dysfunction induced by palmitate. MitoQ and apocynin improve the 
impaired aortic relaxation in response to ACh, induced by palmitate. Results are mean ± SEM; N = 8-12. 
*P<0.05, **P<0.01 and ***P<0.001 versus control, and #P<0.05, ##P<0.01 and ###P<0.001 versus PAL; 
CT, control; PAL, palmitate; ACh, acetylcholine. 
 
Figure 8. Glycomimetics reduce vascular ROS levels by reducing NADPH oxidase activity ex vivo. 
(A) aortic rings were incubated with 100 µmol/L palmitate and 1 or 10 µmol/L of C1-C4 for 24 hours and 
the level of red fluorescence was measured in sections of aorta incubated with DHE. Treatment of aortic 
rings with palmitate for 24 hours increased staining in adventitial, medial and endothelial cells. Co-
incubation of rings with either 1 or 10 µmol/L C1-C4 produced a significant (P<0.001) reduction in the red 
fluorescence. (B) NADPH oxidase activity increased in aortic rings treated palmitate for 24 hours. Both 
doses of C1-C4 reduce palmitate-induced NADPH oxidase activity. Results are mean ± SEM; N = 6. 
***P<0.001 versus control, and ##P<0.01 and ###P<0.001 versus PAL. PAL, palmitate; NADPH oxidase, 
nicotinamide adenine dinucleotide phosphate oxidase; DHE, dihydroethidium. Scale bar = 50 µm. X400. 
 
Figure 9. Schematic diagram demonstrating the protective effects of small molecule glycomimetics 
against FFA-induced endothelial dysfunction. FFA, free fatty acid; Akt, protein kinase B, eNOS, 
endothelial nitric oxide synthase; NO, nitric oxide; Nrf2, nuclear factor-erythroid 2-related factor 2; NQO-
1, NAD(P)H:quinone oxido-reductase 1; HO-1, heme oxygenase-1; O2•−, superoxide radical; ONOO•, 
peroxynitrite; GPx; glutathione peroxidase; GST, glutathione-S-transferase; SOD, superoxide dismutase; 
CAT, catalase; ARE, antioxidant response element. 
 
